Evaluating Whether Hyperbaric Oxygen Therapy Can Improve VO₂-Max and Reduce Inflammation Markers in Healthy Adults Ages 30-60.

Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age30-60
SponsorUniversity of Texas at Austin

About this trial

The purpose of this study is to determine whether hyperbaric oxygen therapy (HBOT) at 1.75 atmospheres of pressure (ATA) improves cardiovascular fitness (VO₂ max) and reduces inflammation in healthy adults. HBOT involves breathing pure oxygen in a pressurized chamber and is considered investigational for this use.

Recent research has shown that different HBOT pressures can have different effects on inflammation. Specifically, some inflammatory cytokines (measurable markers of inflammation in the body) appear to decrease at low pressures like 1.3 ATA, while a different set of cytokines responds better at higher pressures, such as 2.0 ATA.

Cytokines are small proteins that play a crucial role in cell signaling, particularly within the immune system. They help regulate inflammation, infection response, and overall immune function. While some cytokines promote inflammation to fight off threats, others help reduce inflammation when it's no longer needed. An imbalance in cytokines - especially excessive inflammatory cytokines - can contribute to chronic inflammation, cardiovascular disease, and other health issues.

In this study, we are testing an intermediate pressure - 1.75 ATA - to see if we can target both sets of cytokines at once. If successful, this approach could offer broader anti-inflammatory benefits.

We are also interested in how this intermediate pressure may improve VO₂ max, a key indicator of cardiovascular fitness. Since VO₂ max is strongly linked to heart health and overall longevity, finding a safe and effective way to improve it has meaningful implications not just for athletes, but for anyone looking to enhance their fitness and well-being.

Eligibility criteria

This trial accepts healthy volunteers

Qualifiers

physically active individuals with no history of chronic illness or HBOT exposure within the last three months.

Disqualifiers

individuals with contraindications to HBOT, including lung diseases or claustrophobia.

Trial design

Design model

Single group

Treatments tested in this trial

  • Hyperbaric Oxygen Therapy

    Device

    24 Hyperbaric Oxygen Therapy, each lasting 100 minutes, 3 times a week for 8 weeks.

Treatment groups

30 Participants
are divided into 1 treatment group
Group A: Hyperbaric Oxygen Therapy 1.75 atmospheresExperimental treatment 1 intervention

Trial outcomes

Primary outcomes

1

Cytokine levels

Cytokines will be measured via blood analysis. Samples will be taken before treatment, at the midpoint, at the end, and 4 weeks post treatment. This is a measure of inflammation in the body.

Time frame
From enrollment to 4 weeks after the end of treatment (12 weeks after first treatment).
2

VO2 max testing

A treadmill VO2 max test measured before treatment, at treatment midpoint, at the end of treatment, and 4 weeks after conclusion of treatment. This is an indicator of cardiovascular health.

Time frame
From enrollment to 4 weeks post treatment (12 weeks after first treatment)

Secondary outcomes

Other outcomes

Sponsors and contacts

Click on the lead sponsor to view all of their trials.